Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Colorectal cancer (CRC) is the third most common cancer in the world with 150,000 new cases each year. At initial diagnosis, 20% of patients have distant metastasis, thus the cancer has spread to other parts and organs of the body and is not confined to the colon or rectum. 25% to 30% of patients with early stage disease will develop metastasis consequently. The subsequent duration of life for metastatic untreated patients is a heart-aching number accounting for a maximum of 9 months.

Currently, using combination therapy approaches, overall survival lengths has been extended to 20 months. The standard of care for metastatic CRC is surgery followed by chemotherapy. There are several approved chemotherapeutic drugs, one of which is the administration of 5-fluorouracil (5FU) with oxaliplatin given mainly through the course of 12 month,s biweekly. The response rate for this treatment is 29%.

Therapy based upon the biology of an individual’s tumour rather than established histopathologic and anatomic classification is an approach that promises to optimise the use of existing therapies. Gene expression analysis offers the potential to measure genome-wide activity which can be used to predict response to current treatments. My project aims at creating a predictive model that can determine which patients are sensitive or resistant to different chemotherapeutic treatment.

In the future, if we, or any other research group, succeeded in reaching this purpose, we would be able to identify the 71% of patients who may not benefit from chemotherapy. I think modifying the standard of care for CRC will have impactful results on the life of patients and this is our ultimate goal as cancer researchers.

Blog posts

Oncology and World Mental Health Day 2022

In celebration of World Mental Health day on the 10 October, the Department of Oncology opened its doors to the rest of the Medical Sciences Division and hosted a range of exciting workshops, activities and lectures in order to promote better awareness around mental health.

Dr Lennard Lee recognised as one of 21 outstanding young physicians below the age of 40

The Departmental academic clinical lecturer receives this recognition and was invited to take part in the InterAcademy Partnership Young Physician Leaders Programme 2022 in Berlin.